HEMATOPOIETIC ENGRAFTMENT FROM A MINIMAL NUMBER OF APHERESIS PROCEDURES AFTER MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS WITH CHEMOTHERAPY AND RHG-CSF

被引:4
作者
CANTIN, G
MARCHANDLAROCHE, D
BOUCHARD, MM
DEMERS, C
LEBLOND, PF
LYONNAIS, L
PETITCLERC, C
DELAGE, R
机构
[1] Centre d'Hématologie, d'Immunologie Clinique, Hôpital du Saint-Sacrement, Québec, Que. G1S 4L8
来源
TRANSFUSION SCIENCE | 1995年 / 16卷 / 02期
关键词
D O I
10.1016/0955-3886(95)97397-I
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a cohort of 13 patients, peripheral blood stem cells (PBSC) were harvested by apheresis after mobilization with chemotherapy and rhG-CSF. Nine patients who had excellent mobilization were transplanted with PBSC concentrates from a minimal number of apheresis procedures (mean of 1.5, range = 1-3). During collection, the number of circulating progenitors was on average 50 times higher than those observed at the steady state in the peripheral blood of healthy unstimulated individuals. The mean number of CFU-GM/kg reinfused per patient was 28.1 x 10(4) (range = 18.0-50 x 10(4)). The use of rhG-CSF, at either 1 or 5 mu g/kg/day, resulted in a significantly greater yield of CFU-GM per mononuclear cells than that observed previously in a comparable group of patients receiving chemotherapy alone. Prompt and durable engraftment occurred after myeloablative chemotherapy. The average duration of absolute neutropenia was 9 days. Transfusion requirements were low with an average of four packed red cell units and two platelet transfusions per patient. The shortest follow-up is 5 months and the longest is 20+ months. The convenience of this new approach to support myeloablative therapy offers new possibilities for the administration of a higher dose-intensity of chemotherapeutic agents. A limited number of apheresis procedures timely harvested will improve the cost effectiveness of transplant programs.
引用
收藏
页码:145 / 154
页数:10
相关论文
共 22 条
[1]  
Gale, Henon, Juttner, Blood stem cell transplants come of age: meeting report, Bone Marrow Transplant, 9, pp. 151-155, (1992)
[2]  
To, Roberts, Haylock, Dyson, Brandford, Thorp, Ho, Dart, Horvath, Davy, Et al., Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants, Bone Marrow Transplant, 9, pp. 277-284, (1992)
[3]  
Juttner, To, Haylock, Dyson, Thorp, Dart, Ho, Horvath, Bardy, Autologous blood stem cell transplantation, Transplant Proc, 21, pp. 2929-2931, (1989)
[4]  
Lowry, Tabbara, Peripheral blood hematopoietic stem cell transplantation: current concepts, Exp Hematol, 20, pp. 937-942, (1992)
[5]  
Gianni, Siena, Bregni, Tarella, Stern, Pileri, Bonadonna, Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for auto-transplantation, Lancet, 2, pp. 580-584, (1989)
[6]  
Haas, Hohaus, Egerer, Ehrhardt, Witt, Hunstein, Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for auto-grafting in patients not eligible for bone marrow harvest, Bone Marrow Transplant, 9, pp. 459-465, (1992)
[7]  
Sheridan, Begley, Juttner, Szer, To, Maher, McGrath, Morstyn, Fox, Effect of peripheral blood progenitor cells mobilised by G-CSF (Filgastrim) on platelet recovery after high-dose chemotherapy, Lancet, 339, pp. 640-644, (1992)
[8]  
Hohaus, Goldschmidt, Ehrhardt, Haas, Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF, Exp Hematol, 21, pp. 508-514, (1993)
[9]  
Craig, Anthony, Stewart, Thomson, Gillon, Parker, Peripheral blood stem cell mobilization using high dose cyclophosphamide and G-CSF in pretreated patients with lymphoma, Br J Haematol, 85, pp. 210-212, (1993)
[10]  
Teshima, Harada, Takamatsu, Makino, Taniguchi, Inaba, Kondo, Tanaka, Akashi, Minamishima, Et al., Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for auto-grafting, Bone Marrow Transplant, 10, pp. 215-220, (1992)